• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Alkermes plc (Amendment)

    6/28/23 8:00:11 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALKS alert in real time by email
    SC 13D/A 1 brhc20055088_sc13da.htm SC 13D/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No. 15)*

    Alkermes Public Limited Company
    (Name of Issuer)

    Ordinary shares, $0.01 par value
    (Title of Class of Securities)

    G01767105
    (CUSIP Number)

    Mark DiPaolo
    Senior Partner, General Counsel
    Sarissa Capital Management LP
    660 Steamboat Road
    Greenwich, CT 06830
    203-302-2330
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    June 28, 2023
    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐
     
    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
     
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. G01767105
    Page 2 of 4 Pages
    SCHEDULE 13D
    This Amendment No. 15 to Schedule 13D (“Amendment No. 15”) relates to ordinary shares, par value $0.01 per share (“Common Stock” and, such shares, the “Shares”), issued by Alkermes Public Limited Company, a company incorporated under the laws of Ireland (the “Issuer”), and amends the initial statement on Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on May 10, 2021 (the “Initial Schedule 13D”), as amended by Amendment No. 1 to Schedule 13D filed on May 27, 2021, Amendment No. 2 to Schedule 13D filed on September 10, 2021, Amendment No. 3 to Schedule 13D filed on November 19, 2021, Amendment No. 4 to Schedule 13D filed on January 10, 2022, Amendment No. 5 to Schedule 13D filed on July 6, 2022, Amendment No. 6 to Schedule 13D filed on October 7, 2022, Amendment No. 7 to Schedule 13D filed on February 6, 2023, Amendment No. 8 to Schedule 13D filed on June 5, 2023, Amendment No. 9 to Schedule 13D filed on June 12, 2023, Amendment No. 10 to Schedule 13D filed on June 14, 2023, Amendment No. 11 to Schedule 13D filed on June 16, 2023, Amendment No. 12 to Schedule 13D filed on June 21, 2023, Amendment No. 13 to Schedule 13D filed on June 23, 2023 and Amendment No. 14 to Schedule 13D filed on June 27, 2023 (the Initial Schedule 13D, as so amended, the “Schedule 13D”), on behalf of the Reporting Persons, to furnish the additional information set forth herein. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.

    Item 4.
    Purpose of Transaction.

    Item 4 of the Schedule 13D is hereby amended to include the following:

    On June 28, 2023, Sarissa Capital issued the press release attached as Exhibit 11 hereto.

    Item 7.
    Material to Be Filed as Exhibits.

    Item 7 of the Schedule 13D is hereby amended to include the following:

    Exhibit 11 - Press Release, June 28, 2023


    CUSIP No. G01767105
    Page 3 of 4 Pages
    SCHEDULE 13D
    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated:  June 28, 2023
     
       
    SARISSA CAPITAL MANAGEMENT LP
     
       
    By:
    /s/ Mark DiPaolo
     
     
    Name: Mark DiPaolo
     
     
    Title: Senior Partner, General Counsel
     
       
    /s/Alexander J. Denner
     
    Alexander J. Denner
     


    CUSIP No. G01767105
    Page 4 of 4 Pages
    SCHEDULE 13D
    INDEX TO EXHIBITS

    Exhibit 1 - Form 8-K of the Issuer filed with the U.S. Securities and Exchange Commission on April 30, 2021 (incorporated by reference in this Schedule 13D)*

    Exhibit 2 - Joint Filing Agreement of the Reporting Persons, dated as of May 10, 2021*

    Exhibit 3 - Press Release, July 6, 2022*

    Exhibit 4 - Press Release, June 5, 2023*

    Exhibit 5 - Press Release, June 9, 2023*

    Exhibit 6 - Press Release, June 13, 2023*

    Exhibit 7 - Press Release, June 15, 2023*

    Exhibit 8 - Press Release, June 20, 2023*

    Exhibit 9 - Press Release, June 22, 2023*

    Exhibit 10 - Press Release, June 26, 2023*

    Exhibit 11 - Press Release, June 28, 2023

    * Previously filed.



    Get the next $ALKS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALKS

    DatePrice TargetRatingAnalyst
    6/17/2025$42.00Neutral → Buy
    UBS
    5/28/2025$45.00Buy
    Needham
    3/13/2025$40.00Sector Perform
    RBC Capital Mkts
    3/4/2025$21.00 → $38.00Sell → Neutral
    UBS
    2/11/2025$40.00Buy
    Deutsche Bank
    11/5/2024$25.00 → $36.00Hold → Buy
    Stifel
    6/17/2024$34.00Buy
    TD Cowen
    3/19/2024$37.00Outperform
    Robert W. Baird
    More analyst ratings

    $ALKS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Chief Commercial Officer Nichols Christian Todd sold $210,143 worth of Ordinary Shares (6,667 units at $31.52), decreasing direct ownership by 7% to 86,208 units (SEC Form 4)

      4 - Alkermes plc. (0001520262) (Issuer)

      6/10/25 4:39:56 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wright Christopher I converted options into 3,301 units of Ordinary Shares and covered exercise/tax liability with 793 units of Ordinary Shares, increasing direct ownership by 12% to 23,013 units (SEC Form 4)

      4 - Alkermes plc. (0001520262) (Issuer)

      6/10/25 4:37:23 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wright Christopher I covered exercise/tax liability with 1,924 units of Ordinary Shares and converted options into 8,013 units of Ordinary Shares, increasing direct ownership by 42% to 20,505 units (SEC Form 4)

      4 - Alkermes plc. (0001520262) (Issuer)

      6/2/25 4:34:11 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care